Teikoku Pharma USA has entered into an exclusive license agreement with Link Health Group to develop market, sell, and distribute Lidoderm in China. Lidoderm offers relief of the pain associated with post-herpetic neuralgia (PHN). It is a combination of lidocaine in a soft hydrogel plaster combining efficacious treatment with proven tolerability, safety and simple handling.
Lidoderm has been approved by the U.S. FDA and by the European authorities under the name Versatis.
“We are very excited to license our Lidoderm product to Link Health, who has in-depth expertise in the clinical development and approval process of products in China. We are confident that Lidoderm can address unmet medical needs for the PHN patients in China,” said Paul Mori, Chief Executive Officer of TPU.
Under the terms of the agreement, Link Health will pay TPU near-term milestones, including an upfront cash payment, an additional milestone payment based upon the timing of CFDA approval, as well as sales milestones and double-digit royalties on net sales.
“We feel excited for the opportunity to distribute Lidoderm in China, and we are also very confident in its registration and development, under the current policy by CFDA. Lidoderm will be the first TPU product approved and will be the flagship product in market of China,” said Yan Song, the CEO of Link Health.
LIDODERM (lidocaine patch 5%) is comprised of an adhesive material containing 5% lidocaine, which is applied to a non-woven polyester felt backing and covered with a polyethylene terephthalate (PET) film release liner. The release liner is removed prior to application to the skin. The size of the patch is 10 cm x 14 cm.